Trial Profile
A Multicenter, Uncontrolled, Open-label Phase 3 Trial of OPC-41061 in Patients With Hepatic Oedema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Apr 2017
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Ascites; Oedema
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Otsuka Pharmaceutical
- 19 Apr 2014 New trial record
- 24 Aug 2011